World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
41009
World Ranking
15862
National Ranking
19

Research.com Recognitions

  • 1994 - Prize of the Foundation for Polish Science - Nagroda Fundacji na rzecz Nauki Polskiej for his studies into new immunological mechanisms in autoimmune diseases of the nervous system, Multiple Sclerosis in particular

Overview

Krzysztof Selmaj is affiliated with the University of Warmia and Mazury in Olsztyn, Poland. Their research primarily focuses on medicine, with a significant body of work spanning pathology and forensic medicine, immunology, oncology, and neurology. The main domain of research involves the study of multiple sclerosis and related neurological disorders.

The scientist has contributed extensively to several research topics, including:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Immunotherapy and Immune Responses
  • Polyomavirus and Related Diseases
  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Fungal Plant Pathogen Control

Frequent co-authors collaborating with Krzysztof Selmaj include:

  • Hans-Peter Hartung
  • Bruce Cree
  • Eva Havrdová
  • Xavier Montalbán
  • Lawrence Steinman

They have published extensively in major venues relevant to neurological and immunological research. The most frequent publication venues are:

  • Neurology
  • Multiple Sclerosis Journal
  • Multiple Sclerosis and Related Disorders
  • Journal of Neurology
  • Frontiers in Neurology

Recent significant papers authored or co-authored by Krzysztof Selmaj encompass the following:

  • "Ofatumumab versus Teriflunomide in Multiple Sclerosis", 2020, New England Journal of Medicine
  • "Myelin-oligodendrocyte glycoprotein antibody-associated disease", 2021, The Lancet Neurology
  • "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis", 2022, New England Journal of Medicine
  • "Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study", 2020, CNS Drugs
  • "Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study", 2021, Multiple Sclerosis Journal

Krzysztof Selmaj has been recognized with the Prize of the Foundation for Polish Science (Nagroda Fundacji na rzecz Nauki Polskiej) in 1994 for research into new immunological mechanisms in autoimmune diseases of the nervous system, specifically multiple sclerosis.

Best Publications

  • A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

    Ludwig Kappos;Ernst Wilhelm Radue;Paul O'Connor;Chris Polman

  • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer

  • Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

    Krzysztof W. Selmaj;Cedric S. Raine

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

    R. H.S.R. Roxburgh;S. R. Seaman;T. Masterman;A. E. Hensiek

  • Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

    K Selmaj;C S Raine;B Cannella;C F Brosnan

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

    Camms Trial Investigators;Alasdair J Coles;D Alastair S Compston;Krzysztof W Selmaj

  • Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor.

    K W Selmaj;M Farooq;W T Norton;C S Raine

  • Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Stephen L. Hauser;Amit Bar-Or;Jeffrey A. Cohen;Giancarlo Comi

  • Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin.

    K Selmaj;C S Raine;M Farooq;W T Norton

  • Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.

    K. Selmaj;C. S. Raine;A. H. Cross

  • Myelin-oligodendrocyte glycoprotein antibody-associated disease.

    Romain Marignier;Romain Marignier;Yael Hacohen;Alvaro Cobo-Calvo;Anne Katrin Pröbstel

  • Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis.

    Krzysztof Selmaj;Celia F. Brosnan;Cedric S. Raine

  • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

    G Giancarlo Comi;A. Pulizzi;Marco Rovaris;O. Abramsky

  • Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

    Ralf Gold;Gavin Giovannoni;Krzysztof Selmaj;Eva Havrdova

Frequent Co-Authors

Eva Havrdova
Eva Havrdova Charles University
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Amit Bar-Or
Amit Bar-Or University of Pennsylvania
Ralf Gold
Ralf Gold Ruhr University Bochum
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Cedric S. Raine
Cedric S. Raine Albert Einstein College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers but seeking alternative routes to becoming a doctor, several online degree options can open doors to healthcare professions. One increasingly popular choice is nursing, a field with high demand and diverse opportunities for advancement.

Students looking for the fastest entry into nursing may consider the cheapest online accelerated bsn programs. These programs are ideal for those who already hold a non-nursing bachelor’s degree and want to transition quickly into the nursing workforce.

For registered nurses aiming to expand their qualifications, rn to bsn online programs offer a flexible path to a bachelor’s degree, improving career prospects and earning potential. Meanwhile, non-nurses with a bachelor’s degree can explore entry level msn programs online to become advanced practice nurses directly.

Nurses interested in leadership or research roles might pursue a phd in nursing. This high-level degree prepares graduates for positions in academia, policy, or advanced clinical practice. These online pathways offer flexible and affordable options for entering or advancing within the healthcare field.

Best Scientists Citing Krzysztof Selmaj

Trending Scientists

Recently Published Articles